Part of the global Pharmaceutical Packaging Innovation (PPI) Business Unit of Bilcare Research AG, Bilcare Research offers a variety of mono and barrier blister films to the pharmaceutical packaging industry.
“This investment in a new laminating line is just the latest component of our continued growth strategy to meet the needs of the rapidly evolving business models of the global pharmaceutical industry. We see increased demand across our entire range of Bilcare Aclar laminates, from both, ethical and generic pharmaceutical companies,” said Kevin Stevens, president and managing director of Bilcare Research. “The lamination line is a further execution of Bilcare’s strategic investment of €50 Million and is a natural progression to the industry-specific segregation project for our PPI production. The new capacity will be fully available before the end of 2016.”